Evidence map›Paper›PMID 34676334›Full record

ArticleMedical cannabis and cannabinoids2019

Prescription of a THC/CBD-Based Medication to Patients with Dementia: A Pilot Study in Geneva.

Barbara Broers, Zacharie Patà, Aline Mina, James Wampfler, Christian de Saussure, Sophie Pautex

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical cannabis and cannabinoids, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
5.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Cannabinoids for the treatment of dementia.The Cochrane database of systematic reviews · 2021
    Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Cannabinoids for Agitation in Alzheimer's Disease.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2021
    Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Medical cannabis and cannabinoids
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Barbara BroersUnit of Dependencies, Department of Primary Care and Community Medicine, Geneva University Hospitals, Geneva, Switzerland.
Zacharie PatàFaculty of Medicine, University of Geneva, Geneva, Switzerland.
Aline MinaFaculty of Medicine, University of Geneva, Geneva, Switzerland.
James WampflerEMS "Les Tilleuls,", Geneva, Switzerland.
Christian de SaussureEMS "Les Tilleuls,", Geneva, Switzerland.
Sophie PautexDepartment of Palliative Medicine, Geneva University Hospitals, Geneva, Switzerland.
University of Geneva · CHUniversity Hospital of Geneva · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDementia is increasing worldwide. No effective medication is currently available for the treatment of the underlying disease and accompanying behavioral symptoms. Cannabinoids might have a beneficial effect, but clinical studies with (low-dose) synthetic THC have not been conclusive.

objectiveTo test the acceptability, practical aspects, and clinical outcomes of the introduction of a THC/CBD-based oral medication in severely demented patients in a specialized nursing home in Geneva.

methodsThis was a prospective observational study.

resultsTen female demented patients with severe behavior problems received oral medication with on average 7.6 mg THC/13.2 mg CBD daily after 2 weeks, 8.8 mg THC/17.6 mg CBD after 1 month, and 9.0 mg THC/18.0 mg CBD after 2 months. The THC/CBD-based oil was preferred. Neuropsychiatric Inventory, Cohen-Mansfield Agitation Inventory score, and a behavior problem visual analog scale decreased by 40% after 2 months, rigidity score by 50%. Half of the patients decreased or stopped other psychotropic medications. The staff appreciated the decrease in rigidity, making daily care and transfers easier, the improved direct contact with the patients, the improvement in behavior, and the decrease in constipation with less opioids. There was no withholding of the medication for reasons of side effects, and the effects persisted after 2 months.

conclusionsAn oral cannabis extract with THC/CBD, in higher dosages than in other studies, was well tolerated and greatly improved behavior problems, rigidity, and daily care in severely demented patients.

Indexed as

CannabinoidsDementiaTHC/CBDTreatment

Identifiers

PMID34676334
PMCPMC8489328
OpenAlexW2930298652

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.